Phronesis AI develops an intuitive deep-learning platform for the autonomous design of small molecule therapeutics. This generative AI technology enables researchers to create and screen novel compounds faster and more cost-effectively. The platform accelerates drug discovery across therapeutic areas including oncology, CNS disorders, and metabolic diseases.
Funding
$300K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery is a slow, expensive, and inefficient process, often taking many years and significant investment to identify viable drug candidates. Small and medium-sized pharmaceutical companies often lack the resources to compete with larger firms in this high-stakes environment.
Solution
Phronesis Artificial Intelligence offers the Lime Drug Design™ platform, an AI-driven solution for fully autonomous de novo drug design. This platform accelerates the drug discovery process by automating the generation and evaluation of novel drug candidates. By leveraging advanced AI algorithms, Lime Drug Design™ enables small and medium-sized companies to efficiently identify promising drug leads and compete more effectively in the pharmaceutical market.
Target Audience
The primary target audience includes small and medium-sized pharmaceutical companies seeking to expedite drug discovery and compete with larger firms, as well as researchers and scientists involved in drug development.
Features
- AI-powered algorithms for autonomous de novo drug design
- Rapid generation and evaluation of novel drug candidates
- Prediction of IC50 values, selectivity, and culture test results
- Visualization tools for analyzing protein binding interactions
- Beta platform available for public use